Prevalence of cardiometabolic diseases among ART-naïve people with HIV: A global systematic review and meta-analysis.

HIV MedMay 6, 2026 (epub)
Clinical ResearchInfectious DiseasesEndocrinology

Peter Vanes Ebasone, Anastase Dzudie, Nasheeta Peer et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis assessed the global prevalence of cardiometabolic diseases (CMDs) among ART-naïve people with HIV (PWH). Analyzing 184 studies with 424,629 participants, the study found a global pooled prevalence of 14.2% for hypertension and 3.6% for diabetes, among other CMDs. Significant regional variations were noted.

Key findings

  • Global prevalence of hypertension among ART-naïve PWH was 14.2% (95% CI: 12.4-16.1).
  • Diabetes prevalence was found to be 3.6% (95% CI: 2.9-4.3).
  • Obesity based on body mass index was 11.5% (95% CI: 10.3-12.9).
  • 54.6% (95% CI: 48.2-61.0) had low high-density lipoprotein cholesterol.

Why it matters

The rising prevalence of CMDs among ART-naïve PWH underscores the need for early screening and intervention. Understanding these trends can help inform public health strategies and improve patient outcomes in HIV care.

Source

PubMed · PMID 42091237

Published in HIV Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Infectious Diseases

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.